level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.tetrabenazinesolifenacin and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.tipranavirtipranavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.toremifenesolifenacin and toremifene both increase QTc interval. Avoid or Use Alternate Drug.trazodonesolifenacin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.tucatinibtucatinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.umeclidinium bromide/vilanterol inhaledsolifenacin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.solifenacin, umeclidinium bromide/vilanterol inhaled. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Concomitant use with other anticholinergic-containing drugs may lead to additive anticholinergic adverse effects.vandetanibsolifenacin and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.vemurafenibsolifenacin and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.vilanterol/fluticasone furoate inhaledsolifenacin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.voriconazolesolifenacin and voriconazole both increase QTc interval. Avoid or Use Alternate Drug.voxelotorvoxelotor will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.ziprasidonesolifenacin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (232)abobotulinumtoxinAabobotulinumtoxinA increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .aclidiniumsolifenacin and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.albuterolalbuterol and solifenacin both increase QTc interval. Use Caution/Monitor.alfuzosinsolifenacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and solifenacin both increase QTc interval. Use Caution/Monitor.amantadinesolifenacin, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.amisulprideamisulpride and solifenacin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylinesolifenacin and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and amitriptyline both increase QTc interval. Use Caution/Monitor.amobarbitalamobarbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.amoxapinesolifenacin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and amoxapine both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosanticholinergic/sedative combos and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.apomorphineapomorphine and solifenacin both increase QTc interval. Use Caution/Monitor.aprepitantaprepitant will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.arformoterolarformoterol and solifenacin both increase QTc interval. Use Caution/Monitor.aripiprazolesolifenacin decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.aripiprazole increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.aripiprazole and solifenacin both increase QTc interval. Use Caution/Monitor.armodafinilarmodafinil will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atazanaviratazanavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atomoxetineatomoxetine and solifenacin both increase QTc interval. Use Caution/Monitor.atracuriumatracurium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineatropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMatropine IV/IM and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.bedaquilinesolifenacin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelladonna alkaloidsbelladonna alkaloids and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumbelladonna and opium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidolsolifenacin decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.benperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropinebenztropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholbethanechol increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.bosentanbosentan will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.budesonidebudesonide will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butabarbitalbutabarbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.butalbitalbutalbital will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbacholcarbachol increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.cenobamatecenobamate will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cevimelinecevimeline increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazinesolifenacin decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.ciprofloxacinsolifenacin and ciprofloxacin both increase QTc interval. Use Caution/Monitor.cisatracuriumcisatracurium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipraminesolifenacin and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and clomipramine both increase QTc interval. Use Caution/Monitor.clozapinesolifenacin decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.clozapine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.clozapine and solifenacin both increase QTc interval. Use Caution/Monitor.conivaptanconivaptan will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.cortisonecortisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.crizotinibcrizotinib increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crofelemercrofelemer increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.cyclizinecyclizine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclosporinecyclosporine will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.darifenacindarifenacin will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.darifenacin and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.darunavirdarunavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibdasatinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinib and solifenacin both increase QTc interval. Use Caution/Monitor.degarelixdegarelix and solifenacin both increase QTc interval. Use Caution/Monitor.desipraminesolifenacin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.solifenacin and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazinedeutetrabenazine and solifenacin both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexamethasonedexamethasone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.DHEA, herbalDHEA, herbal will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dicyclominedicyclomine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.diltiazemdiltiazem will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.diphenhydraminediphenhydramine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.disopyramidesolifenacin and disopyramide both increase QTc interval. Use Caution/Monitor.dolasetrondolasetron and solifenacin both increase QTc interval. Use Caution/Monitor.donepezildonepezil increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil transdermaldonepezil transdermal, solifenacin. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinsolifenacin and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinsolifenacin and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepin and solifenacin both increase QTc interval. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.droperidolsolifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.droperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.duvelisibduvelisib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.echothiophate iodideechothiophate iodide increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzefavirenz will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.efavirenz and solifenacin both increase QTc interval. Use Caution/Monitor.elagolixelagolix decreases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibencorafenib, solifenacin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.enzalutamideenzalutamide will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.escitalopramescitalopram increases toxicity of solifenacin by QTc interval. Use Caution/Monitor.eslicarbazepine acetateeslicarbazepine acetate will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.etravirineetravirine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fesoterodinefesoterodine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.fingolimodfingolimod and solifenacin both increase QTc interval. Use Caution/Monitor.flavoxateflavoxate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainidesolifenacin and flecainide both increase QTc interval. Use Caution/Monitor.fluconazolefluconazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fludrocortisonefludrocortisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fluoxetinesolifenacin and fluoxetine both increase QTc interval. Use Caution/Monitor.fluphenazinesolifenacin decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.fluphenazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.solifenacin and fluphenazine both increase QTc interval. Use Caution/Monitor.fluvoxaminefluvoxamine will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.solifenacin and fluvoxamine both increase QTc interval. Use Caution/Monitor.fosamprenavirfosamprenavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosaprepitantfosaprepitant will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosphenytoinfosphenytoin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fostemsavirsolifenacin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.galantaminegalantamine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.gemifloxacingemifloxacin and solifenacin both increase QTc interval. Use Caution/Monitor.gemtuzumabsolifenacin and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and solifenacin both increase QTc interval. Use Caution/Monitor.glycopyrrolateglycopyrrolate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.goserelinsolifenacin and goserelin both increase QTc interval. Use Caution/Monitor.granisetrongranisetron and solifenacin both increase QTc interval. Use Caution/Monitor.grapefruitgrapefruit will increase the level